Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The CIRCULATE study evaluates the adjuvant therapy in patients with colon cancer UICC stage
II. The primary aim of the study is to compare the disease free survival in patients who are
positive for postoperative circulating tumour DNA with vs. without capecitabine.